Literature DB >> 33707179

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers.

Nikhil V Kamat1,2, Evan Y Yu1,3, John K Lee4,2,3.   

Abstract

Targeting prostate-specific membrane antigen (PSMA) has important therapeutic ramifications, more recently including immune oncology. Data were recently presented on the preclinical efficacy of a half-life extended bispecific T-cell engager, AMG 160, which binds PSMA and CD3 to induce T-cell-driven cytolytic activity against prostate cancer.See related article by Deegen et al., p. 2928. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33707179      PMCID： PMC8127346          DOI： 10.1158/1078-0432.CCR-21-0355

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  T cell-engaging therapies - BiTEs and beyond.

Authors:  Maria-Elisabeth Goebeler; Ralf C Bargou
Journal:  Nat Rev Clin Oncol       Date:  2020-04-02       Impact factor: 66.675

2.  The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.

Authors:  Petra Deegen; Oliver Thomas; Olivier Nolan-Stevaux; Shyun Li; Joachim Wahl; Pamela Bogner; Famke Aeffner; Matthias Friedrich; Michael Z Liao; Katja Matthes; Doris Rau; Benno Rattel; Tobias Raum; Peter Kufer; Angela Coxon; Julie M Bailis
Journal:  Clin Cancer Res       Date:  2021-01-27       Impact factor: 12.531

3.  Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.

Authors:  Mayassa J Bou-Dargham; Linlin Sha; Qing-Xiang Amy Sang; Jinfeng Zhang
Journal:  BMC Cancer       Date:  2020-06-18       Impact factor: 4.430

Review 4.  Past, Current, and Future of Immunotherapies for Prostate Cancer.

Authors:  Adeline N Boettcher; Ahmed Usman; Alicia Morgans; David J VanderWeele; Jeffrey Sosman; Jennifer D Wu
Journal:  Front Oncol       Date:  2019-09-11       Impact factor: 6.244

5.  Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.

Authors:  Horst-Dieter Hummel; Peter Kufer; Carsten Grüllich; Ruth Seggewiss-Bernhardt; Barbara Deschler-Baier; Manik Chatterjee; Maria-Elisabeth Goebeler; Kurt Miller; Maria de Santis; Wolfgang Loidl; Christian Dittrich; Andreas Buck; Constantin Lapa; Annette Thurner; Sabine Wittemer-Rump; Gökben Koca; Oliver Boix; Wolf-Dietrich Döcke; Ricarda Finnern; Helena Kusi; Antoinette Ajavon-Hartmann; Sabine Stienen; Cyrus Michael Sayehli; Bülent Polat; Ralf C Bargou
Journal:  Immunotherapy       Date:  2020-11-10       Impact factor: 4.196
  5 in total
  1 in total

1.  Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design.

Authors:  Eske N Glud; Martin Rasmussen; Yonghui Zhang; Ole A Mandrup; Paul Vinu Salachan; Michael Borre; Karina Dalsgaard Sørensen; Kenneth A Howard
Journal:  Br J Cancer       Date:  2022-10-15       Impact factor: 9.075
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.